Gene editing technique helps find cancer's weak spots

March 20, 2017, University of California - San Diego
A network of synthetic-lethal interactions connecting commonly mutated genes to potential drug targets. Credit: UC San Diego Health

Genetic mutations that cause cancer also weaken cancer cells, creating an opportunity for researchers to develop drugs that will selectively kill them, while sparing normal cells. This concept is called "synthetic lethality" because the drug is only lethal to mutated (synthetic) cells. Researchers at UC San Diego School of Medicine and Jacobs School of Engineering developed a new method to search for synthetic-lethal gene combinations.

The technique, published March 20 in Nature Methods, uncovered 120 new opportunities for .

"The ovarian drug olaparib works by synthetic lethality—it inhibits a gene that, when a BRCA gene is also mutated, kills just those ," said John Paul Shen, MD, clinical instructor and postdoctoral fellow at UC San Diego School of Medicine and Moores Cancer Center. "Many other cancers could likely be treated this way as well, but we don't yet know which gene mutation combinations will be synthetic-lethal." Shen was co-first author of the study, along with Dongxin Zhao, PhD, postdoctoral fellow at UC San Diego Jacobs School of Engineering, and Roman Sasik, PhD, computational biologist in the UC San Diego School of Medicine.

To overcome this limitation, the team developed a new method that uses the CRISPR/Cas9 to simultaneously test for thousands of synthetic-lethal interactions. CRISPR/Cas9 works like this: researchers design a "guide" RNA to match the sequence of a specific target gene in a cell. The RNA guides the Cas9 enzyme to the desired spot, where it cuts the DNA. The cell can repair the DNA break, but it does so imprecisely, thereby inactivating the gene.

In this study, the researchers designed a CRISPR/Cas9 system with two guide RNAs: 1) one that targets a that is commonly mutated in cancer and 2) one that targets a gene that could also be disrupted by a cancer drug. They deployed this system against 73 genes in three laboratory cell lines—human cervical cancer, lung cancer and embryonic kidney —for a total of 150,000 gene combinations. Then they measured cell growth and death.

The approach revealed more than 120 new synthetic-lethal interactions.

"Identifying underlying genetic interactions in this way can reveal important functional relationships between , such as contributions to the same protein complex or pathway," co-senior author Trey Ideker, PhD, professor in the UC San Diego School of Medicine, founder of the UC San Diego Center for Computational Biology and Bioinformatics and co-director of the Cancer Cell Map Initiative. "This in turn can impact both our fundamental understanding of biological systems, as well as therapeutics development."

Many of the gene interactions the team identified were synthetic-lethal in just one of the three cell lines tested. This means that synthetic-lethal interactions may be different in different types of cancer. The researchers said this will be an important consideration for future drug development.

"Moving forward, we intend to further refine our technology platform and make it more robust," said co-senior author Prashant Mali, PhD, assistant professor in the Jacobs School of Engineering at UC San Diego. "And we are scaling our cancer genetic networks maps so we can systematically identify new combination therapies."

Explore further: Researchers ID cancer gene-drug combinations ripe for precision medicine

More information: Combinatorial CRISPR–Cas9 screens for de novo mapping of genetic interactions, Nature Methods, nature.com/articles/doi:10.1038/nmeth.4225

Related Stories

Researchers ID cancer gene-drug combinations ripe for precision medicine

July 21, 2016
In an effort to expand the number of cancer gene mutations that can be specifically targeted with personalized therapies, researchers at University of California San Diego School of Medicine and Moores Cancer Center looked ...

CAR T cells more powerful when built with CRISPR, researchers find

February 22, 2017
Researchers from Memorial Sloan Kettering Cancer Center (MSK) have harnessed the power of CRISPR/Cas9 to create more-potent chimeric antigen receptor (CAR) T cells that enhance tumor rejection in mice. The unexpected findings, ...

Researchers identify 'synthetic essentiality' as novel approach for locating cancer therapy targets

February 6, 2017
A new method has been found for identifying therapeutic targets in cancers lacking specific key tumor suppressor genes. The process, which located a genetic site for the most common form of prostate cancer, has potential ...

Researchers chart global genetic interaction networks in human cancer cells

February 2, 2017
Cancer is a heterogeneous disease, with myriad distinct subtypes that differ in their genetic roots. As a result, cancers rely on varied pathways for survival—and respond differently to anticancer agents. The challenge ...

Researchers discover new approach to improve personalized cancer treatments

October 15, 2013
Researchers from the University of Minnesota, Mayo Clinic, and University of Toronto have successfully shown that a new method for targeting mutated cells could create a major breakthrough in a personalized medicine approach ...

Recommended for you

Daily low-dose aspirin may be weapon against ovarian cancer

July 20, 2018
(HealthDay)— One low-dose aspirin a day could help women avoid ovarian cancer or boost their survival should it develop, two new studies suggest.

Discovery of kidney cancer driver could lead to new treatment strategy

July 19, 2018
University of North Carolina Lineberger Comprehensive Cancer Center scientists have uncovered a potential therapeutic target for kidney cancers that have a common genetic change. Scientists have known this genetic change ...

High fruit and vegetable consumption may reduce risk of breast cancer, especially aggressive tumors

July 19, 2018
Women who eat a high amount of fruits and vegetables each day may have a lower risk of breast cancer, especially of aggressive tumors, than those who eat fewer fruits and vegetables, according to a new study led by researchers ...

Sunscreen reduces melanoma risk by 40 per cent in young people

July 19, 2018
A world-first study led by University of Sydney has found that Australians aged 18-40 years who were regular users of sunscreen in childhood reduced their risk of developing melanoma by 40 percent, compared to those who rarely ...

Analysis of prostate tumors reveals clues to cancer's aggressiveness

July 19, 2018
Using genetic sequencing, scientists have revealed the complete DNA makeup of more than 100 aggressive prostate tumors, pinpointing important genetic errors these deadly tumors have in common. The study lays the foundation ...

Complementary medicine for cancer can decrease survival

July 19, 2018
People who received complementary therapy for curable cancers were more likely to refuse at least one component of their conventional cancer treatment, and were more likely to die as a result, according to researchers from ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.